Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005041 · ClinicalTrials.gov registry record · Phase 2
R115777 in Treating Patients With Relapsed Small Cell Lung Cancer
A Phase 2 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005041: Completed Phase 2 study, sponsored by NYU Langone Health.
NCT00005041 is a Phase 2 study that has completed, run by NYU Langone Health. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005041, a Phase 2 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed small cell lung cancer.
Interventions
- DRUG tipifarnib
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-09 |
| Phase | Phase 2 |
What the finished NCT00005041 record still lists
NCT00005041 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which tipifarnib is the first listed.
NCT00005041 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005041 about?
NCT00005041 is a clinical study titled "R115777 in Treating Patients With Relapsed Small Cell Lung Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of R115777 in treating patients who have relapsed small cell lung cancer.
What is the current status of trial NCT00005041?
This trial is currently completed. It is a Phase 2 study. The study started on 1999-09.
What interventions are being tested in trial NCT00005041?
The interventions under investigation include: tipifarnib (DRUG).
Who is sponsoring clinical trial NCT00005041?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia